DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections

Nucleic acid delivery: Instant, wide-ranging protection against influenza A and B A novel innoculation technique involving the injection of antibody-producing plasmid DNA has shown to be effective against influenza in mice. The flu is responsible for up to half a million deaths each year and up to f...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sarah T. C. Elliott, Nicole L. Kallewaard, Ebony Benjamin, Leslie Wachter-Rosati, Josephine M. McAuliffe, Ami Patel, Trevor R. F. Smith, Katherine Schultheis, Daniel H. Park, Seleeke Flingai, Megan C. Wise, Janess Mendoza, Stephanie Ramos, Kate E. Broderick, Jian Yan, Laurent M. Humeau, Niranjan Y. Sardesai, Kar Muthumani, Qing Zhu, David B. Weiner
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
Acceso en línea:https://doaj.org/article/eacd8d537f1948d3bf6f77c99669bab8
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Nucleic acid delivery: Instant, wide-ranging protection against influenza A and B A novel innoculation technique involving the injection of antibody-producing plasmid DNA has shown to be effective against influenza in mice. The flu is responsible for up to half a million deaths each year and up to five million cases of severe disease, while also posing a substantial pandemic threat, even with our current repertoire of vaccines. A team of researchers led by Sarah Elliott and David Weiner of The Wistar Institute of Anatomy and Biology, Philadelphia, developed potent plasmid-based constructs that, once injected, entered hosts’ cells and utilized cellular machinery to encode antibodies protective against a range of influenza A and B subtypes. DNA inoculation conferred acute protection from disease, with treated individuals also being immune to subsequent exposure. This approach warrants further investigation as an alternative technology for practical delivery of monoclonal antibody therapeutics.